First Final Written Decision in Inter Partes Review of Pharmaceutical Related Patents
Client Alert | 2 min read | 06.27.14
On June 20, 2014, the U.S. Patent and Trademark Office's Trial and Appeal Board, for the first time, rendered final written decisions in inter partes review proceedings of pharmaceutical related patents, specifically claims covering compositions for and methods of making and using folate-containing dietary supplements said to address elevated levels of homocysteine in the blood that can lead to cardiovascular, ocular, neurological and skeletal diseases. Since the inter partes review procedure went into effect in September 2012, more than 1350 patent challenges have been initiated, more than 700 trials instituted, and more than 65 final written decisions issued, but these are the first final written decisions in cases involving pharmaceutical related patents. Of particular significance, the Board found all of the challenged patent claims it reviewed to be unpatentable.
The petitions in the four inter partes review proceedings (IPR 2013-00116; IPR 2013-00117; IPR 2013-00118; and IPR 2013-00119) were filed by Gnosis SpA, which had been sued by Merck in the Eastern District of Texas for infringement of certain claims of the four challenged patents. Merck is a licensee of three of the patents, which are owned by South Alabama Medical Science Foundation. The fourth patent is owned by Merck's subsidiary, Merck & Cie. The district court case was stayed pending the inter partes review proceedings.
The Board determined that all of the challenged claims on which it rendered a decision were unpatentable as obvious, with certain of the claims also being unpatentable as anticipated. In each of the four proceedings, the Board determined that the patent owners did not persuasively show a nexus between the asserted objective evidence of nonobviousness and the claims under review. The Board concluded that, on balance, Gnosis's strong evidence of obviousness outweighed the patent owner's objective evidence of non-obviousness, and a preponderance of the evidence supported the findings of unpatentability.
Multiple expert declarations were submitted by both sides in each of the proceedings. In each of the cases, aside from amending the patents to cancel certain challenged claims, the patent owner did not otherwise attempt to substantively amend any of the claims.
The patent owners now have the ability to either file Requests for Reconsideration or to file appeals to the Federal Circuit.
Contacts
Insights
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
On June 22, 2026, President Trump signed two executive orders, “Securing the Nation Against Advanced Cryptographic Attacks” (Quantum Security EO) and “Ushering in the Next Frontier of Quantum Innovation” (Quantum Innovation EO), marking the most significant federal action on quantum technology since the Quantum Computing Cybersecurity Preparedness Act of 2022, which directed agencies to harden their information systems against quantum-enabled hacking. The orders seek to speed the development of quantum computers, which are advanced processors that can calculate multiple possibilities simultaneously and thus solve problems exponentially faster than traditional computers. At the same time, the orders look to protect against the danger that quantum technology can “break” traditional encryption by easily decoding it. Of particular note for government contractors, the Quantum Security EO directs agencies to update federal acquisition regulations to require contractors by 2031 to adopt information processing standards that resist quantum-enabled codebreaking.
Client Alert | 7 min read | 06.24.26
Client Alert | 3 min read | 06.24.26
Client Alert | 4 min read | 06.23.26
EPA Hands Over AI Data Center Regulation to States and Communities to Develop Best Practices
